Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Janssen COVID-19 booster leads to nine-fold increase in neutralizing antibodies

CDC had concluded earlier that J&J vaccine recipients will likely benefit from boosters.

By Brian Buntz | August 25, 2021

JanssenJohnson & Johnson (NYSE:JNJ) has announced that a booster of its viral-vector COVID-19 vaccine led to considerable increases in coronavirus spike-binding antibodies, according to interim data from two Phase 1/2 trials known as VAC31518COV1001 and VAC31518COV2001.

In particular, the boosters led to a nine-fold increase in antibodies relative to levels 28 days after administering the prime dose.

Janssen noted robust increases in participants aged 18 to 55 and those 65 and older who received a reduced booster dose.

The company has submitted the data to the pre-print publisher medRxiv.

Johnson & Johnson had found earlier that the Ad26.COV2.S vaccine elicited significant protection against COVID-19 eight months after the initial vaccination. Those data were published in NEJM.

CDC said on August 18 that recipients of the Johnson & Johnson vaccine will likely benefit from a booster, but that more data are required.

The company is working with regulatory authorities in the U.S. and Europe to obtain authorization for booster doses of the vaccine. In addition, Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) have also begun applying for authorization of booster doses of their respective vaccines.

The Biden administration has signaled its intent to authorize COVID-19 vaccine boosters eight months after the initial vaccination.

The U.S. government provided partial funding for the two Phase 1/2a studies.

After announcing the news, Johnson & Johnson shares dipped 0.67% to $174.21 apiece in mid-day trading.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Janssen Pharmaceuticals, Johnson & Johnson, VAC31518COV1001, VAC31518COV2001
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
How biosimulation and virtual trials can bust through clinical trial roadblocks
Complexity’s counterpoint: Understanding protocol optimization 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE